title: [Third-line treatment of intermittent hepatic arterial infusion for unresectable liver metastases from colorectal cancer].
abstract: We report 6 cases of liver metastases from colorectal cancer with third-line treatment of intermittent hepatic arterial infusion and systemic chemotherapy for unresectable liver metastases with clinical signification of direct invasion to adjacent organs in Stage IV colorectal cancer. Subjects were 19 consecutive patients who underwent R0 surgery to the primary tumor for colorectal carcinoma, pT4, M1 in 1995-2003. We studied the relationship of pathological invasion to adjacent organs of tumor to other clinicopathological factors to prognosis. Of the 19 patients, 11 (57.8%) were R0 surgery to the tumor of metastases. Only 4 (36.7%) patients survived more than 3 years. The patient without excision did not survive for three years. The median survival time was only 8.5 months. Multivariate analysis indicated that only R0 surgery to the tumor of metastases was an independent prognostic factor. The optimum resection for adjacent organs may prolong a survival. But the extended resection is a possibility of shortening the survival time.
authors.affiliation: Dept. of Surgery, Minoh City Hospital.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kato
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Miyake
authors.forename: Takashi
authors.initials: T
authors.lastname: Doi
authors.forename: Minako
authors.initials: M
authors.lastname: Hoshi
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Makari
authors.forename: Satoshi
authors.initials: S
authors.lastname: Oshima
authors.forename: Shouhei
authors.initials: S
authors.lastname: Iijima
authors.forename: Eiji
authors.initials: E
authors.lastname: Kurokawa
authors.forename: Nobuteru
authors.initials: N
authors.lastname: Kikkawa
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D000077146:Irinotecan; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D000077150:Oxaliplatin; D016879:Salvage Therapy
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000077146:Irinotecan; D002166:Camptothecin